TITLE

Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis

AUTHOR(S)
Wallace, W A; Roberts, S N; Caldwell, H; Thornton, E; Greening, A P; Lamb, D; Howie, S E
PUB. DATE
March 1994
SOURCE
Thorax;Mar1994, Vol. 49 Issue 3, p218
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66114953

 

Related Articles

  • Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Bernstein, R.M.; Morgan, S.H.; Chapman, J.; Bunn, C.C.; Mathews, M.B.; Turner-Warick, M.; Hughes, G.R.V. // British Medical Journal (Clinical Research Edition);7/21/1984, Vol. 289 Issue 6438, p151 

    Discusses the function of anti-jo-1 antibody in patients with myositis and cryptogenic fibrosing alveolitis in Great Britain. Definition of myositis; Identification of the antibody by counterimmunoelectrophoresis; Usage of cytotoxic drugs.

  • Cryptogenic Fibrosing Alveolitis Predating Ulcerative Colitis. De Llano, Luis A. Pérez; Lancho, Angel; Del Cerro, J. L. Soilán; López-Rosés, Leopoldo // American Journal of Gastroenterology;Apr1996, Vol. 91 Issue 4, p822 

    Presents a letter to the editor on cryptogenic fibrosing alveolitis predating ulcerative colitis.

  • Minerva.  // BMJ: British Medical Journal (International Edition);04/11/98, Vol. 316 Issue 7138, p1178 

    Presents information on developments in medicine. Information on injuries from snowmobiles; Account on an approach for treating metastatic breast cancer; Survival period of patients with cryptogenic fibrosing alveolitis.

  • What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. Scott, Jonathan; Johnston, Ian; Britton, John // BMJ: British Medical Journal (International Edition);11/3/90, Vol. 301 Issue 6759, p1015 

    Examines the etiology of cryptogenic fibrosing alveolitis in Nottingham, England. Role of the occupational and domestic exposure to dust for the development of the disease; Survival of patients after a month of diagnosed; Evaluation of the restrictive pulmonary function test for the investigation.

  • Pulmonary Fibrosis.  // Current Medical Literature: Respiratory Medicine;2010, Vol. 24 Issue 1, p23 

    The article reviews several studies on pulmonary fibrosis. It cites an investigation on the effect of bosentan in patients with idiopathic pulmonary fibrosis (IPF) in the Bosentan Use in Interstitial Lung Disease-1 (BUILD-1) trial which note that endothelin antagonists do not have any proven...

  • SCIENTIFIC FRONTIERS IN LUNG DISEASE.  // Thorax;Dec2001 Supp, Vol. 56, piii41 

    This article presents various studies related to scientific frontiers in lung disease. The immune pathology of sarcoidosis is characterized by an exaggerated CD4 T cell response to an undefined antigens. Spontaneous remission occurs in the majority of subjects, but 30% of patients develon...

  • Localisation of transforming growth factor β1 and β3 mRNA transcripts in normal and fibrotic human lung. Coker, R. K.; Laurent, G. J.; Jeffery, P. K.; du Bois, R. M.; Black, C. M.; McAnulty, R. J. // Thorax;Jul2001, Vol. 56 Issue 7, p549 

    Background--Transforming growth factor β1 is implicated in the pathogenesis of lung fibrosis. It promotes extracellular matrix accumulation by increasing procollagen synthesis and reducing degradation. TGFβ1 gene and protein expression increase in experimental lung fibrosis, and TGFβ1...

  • Fibrosing alveolitis in patients with RA. Saravanan, V.; Kelly, C. A. // Thorax;Apr2002, Vol. 57 Issue 4, p375 

    Presents a letter to the editor about fibrosing alveolitis in patients with rheumatoid arthritis.

  • Private specificities can dominate the humoral response to self-antigens in patients with cryptogenic fibrosing alveolitis. Robinson, Cleo; Callow, Marinella; Stevenson, Sandra; Robinson, Bruce W. S.; Lake, Richard A. // Respiratory Research;2001, Vol. 2, p119 

    Background: The pathogenetic mechanisms that underlie the interstitial lung disease cryptogenic fibrosing alveolitis (CFA) may involve an immunological reaction to unidentified antigens in the lung, resulting in tissue damage. Method: In order to identify the range of target autoantigens, we...

  • Interstitial lung disease: progress and problems. Bourke, S. J. // Postgraduate Medical Journal;Aug2006, Vol. 82 Issue 970, p494 

    Interstitial lung disease involves all areas of medicine as it often occurs in patients with comorbidities or as a consequence of systemic diseases and their treatment. Typically the physician is faced with a breathless patient, a diffusely abnormal chest radiograph, and a wide differential...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics